Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023
Discover our news
Servier Expands Base4 Partnership to Advance Neuroscience Drug Development
Nicolas Garnier joins Servier as Chief Patient Officer
Data at ASH 2023 Underscores Servier Leadership in Hard-to-Treat Hematologic Malignancies
New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
New Vorasidenib Data at SNO 2023 Bolster Servier’s Neuro-Oncology Clinical Development Program
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in the Treatment of IDH1-mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
Servier Presents Updated Results for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes at the 2023 European Hematology Association (EHA) Congress